Fundraising Fox

Longeveron

NASDAQ: LGVN

Miami, US · Delaware corporation · 2 known investors

longeveron.com ↗

Longeveron is a clinical-stage biotechnology company developing regenerative cell therapies for patients with serious and aging-related conditions. Its programs target rare pediatric heart diseases such as Hypoplastic Left Heart Syndrome and Pediatric Dilated Cardiomyopathy, as well as Alzheimer's disease and aging-related frailty.

BiotechHealthtechLongevityMedical Devicesin /longeveron-inc@LGVNSocial

Founders & leadership

JM
Joshua M. HareFounder
PL
Paul LehrExecutive
LA
Lisa A. LocklearExecutive
WH
Wa'el HashadExecutive
NA
Nataliya AgafonovaExecutive
JC
James ClavijoExecutive
GG
Geoff GreenNamed on SEC filing

Board

RS
Rock SofferBoard director
DS
Donald SofferManager of the Company.
RJ
Roger Joseph HajjarBoard director
NE
Neil E. HareBoard director
NJ
Neha J. MotwaniBoard director

Investors · 2

Maryland TEDCOUpper Marlboro · $500K – $1.5M
TEDCOColumbia

Competitors · 3

by search overlap
Regeneron NASDAQ: REGN www.regeneron.com51 shared keywordsRegeneron is a biopharmaceutical company that develops medicines ranging from biologics to genetic medicines for people with serious diseases across areas such as metabolic disease, ophthalmology, and rare diseases. It runs research and development programs and clinical trials aimed at treating conditions including generalized myasthenia gravis.
Bioworld29 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eledon26 shared keywordsEledon develops tegoprubart, an anti-CD40L antibody in clinical development for preventing rejection in organ transplant recipients. The company focuses on improving long-term graft survival and quality of life for transplant recipients across kidney, liver, and xenotransplantation.

Companies competing with Longeveron for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements

$37.4M disclosed across 4 of 9 rounds · 2017–2026

▶$15.9MraisedMar 2026 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul LehrExecutive Officer
  • Nataliya AgafonovaExecutive Officer
  • Rock SofferDirector
  • George Paletta, Jr.Director
  • Ursula UngaroDirector
  • Stephen H. WillardExecutive Officer
  • Devin BlassExecutive Officer
  • Lisa A. LocklearExecutive Officer
  • Roger Joseph HajjarDirector
  • Joshua M. HareExecutive Officer, Director
Offering amount
$33.5M
Amount sold
$15.9M
Sales commissions
$2.2M
Placement agents
Michael Vasinkevich, Craig Schwabe, Noam Rubinstein, Charles Worthman
First sale
Mar 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.5MofferedJul 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Roger Joseph HajjarDirector
  • Joshua M. HareExecutive Officer, Director
  • Neil E. HareDirector
  • Paul LehrExecutive Officer
  • Neha J. MotwaniDirector
  • Lisa A. LocklearExecutive Officer
  • Richard KenderDirector
  • Ursula UngaroDirector
  • Wa'el HashadExecutive Officer, Director
  • Nataliya AgafonovaExecutive Officer
  • Rock SofferDirector
  • Khoso BaluchDirector
Offering amount
$9.5M
Sales commissions
$630K
Placement agents
Craig Schwabe, Charles Worthman, Michael Vasinkevich, Noam Rubinstein
First sale
Jul 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.4MofferedJun 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Khoso BaluchDirector
  • Paul LehrExecutive Officer
  • Lisa A. LocklearExecutive Officer
  • Rock SofferDirector
  • Richard KenderDirector
  • Neil E. HareDirector
  • Wa'el HashadExecutive Officer, Director
  • Joshua M. HareExecutive Officer, Director
  • Nataliya AgafonovaExecutive Officer
  • Douglas LosordoDirector
  • Ursula UngaroDirector
Offering amount
$9.4M
Sales commissions
$424.5K
Placement agents
Michael Vasinkevich, Charles Worthman, Craig Schwabe, Noam Rubinstein
First sale
Jun 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.4MofferedApr 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Cathy RossDirector
  • Ursula UngaroDirector
  • Khoso BaluchDirector
  • Jeffrey PfefferDirector
  • Wa'el HashadExecutive Officer, Director
  • Neil E. HareDirector
  • Paul LehrExecutive Officer
  • Nataliya AgafonovaExecutive Officer
  • Lisa LocklearExecutive Officer
  • Douglas LosordoDirector
  • Rock SofferDirector
  • Joshua M. HareExecutive Officer, Director
Offering amount
$12.4M
Sales commissions
$436.8K
Placement agents
Charles Worthman, Noam Rubinstein, Craig Schwabe, Michael Vasinkevich
First sale
Apr 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.6MofferedJan 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas LosordoDirector
  • Lisa LocklearExecutive Officer
  • Jeffrey PfefferDirector
  • Joshua M. HareExecutive Officer, Director
  • Nataliya AgafonovaExecutive Officer
  • Neil E. HareDirector
  • Wa'el HashadExecutive Officer, Director
  • Khoso BaluchDirector
  • Cathy RossDirector
  • Rock SofferDirector
  • Ursula UngaroDirector
  • Paul LehrExecutive Officer
Offering amount
$2.6M
Sales commissions
$165.6K
Placement agents
Noam Rubinstein, Michael Vasinkevich, Craig Schwabe, Charles Worthman
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.4MofferedOct 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Cathy RossDirector
  • Rock SofferDirector
  • Douglas LosordoDirector
  • Lisa A. LocklearExecutive Officer
  • Paul LehrExecutive Officer
  • Wa'El HashadExecutive Officer, Director
  • Joshua M. HareExecutive Officer, Director
  • Ursula UngaroDirector
  • Jeffrey PfefferDirector
  • Khoso BaluchDirector
  • Neil E. HareDirector
  • Nataliya AgafonovaExecutive Officer
Offering amount
$8.4M
Sales commissions
$280K
Placement agents
Noam Rubinstein, Michael Vasinkevich, Craig Schwabe, Charles Worthman
First sale
Oct 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20.5MraisedDec 2021 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Geoff GreenExecutive Officer
  • Paul LehrExecutive Officer
  • Ursula UngaroDirector
  • Donald SofferDirector
  • Rock SofferDirector
  • Douglas LosordoDirector
  • Neil HareDirector
  • Erin BorgerDirector
  • Cathy RossDirector
  • Joshua HareExecutive Officer, Director
  • James ClavijoExecutive Officer
Offering amount
$20.5M
Amount sold
$20.5M
Sales commissions
$1.6M
Placement agents
EF Hutton, division of Benchmark Investments, LLC
First sale
Dec 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$955KraisedFeb 2020 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Donald SofferDirector
  • James ClavijoExecutive Officer
  • Neil E. HareDirector
  • Geoff GreenExecutive Officer
  • Joshua M. HareExecutive Officer, Director, Promoter
  • Paul LehrExecutive Officer
Offering amount
$25M
Amount sold
$955K
Minimum investment
$50K
First sale
Oct 2017
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Top Longevity Biotech Startups by Fundraising (2026) – New Market Pitchnewmarketpitch.com · Jul 2026Longeveron Q1 2026 results and cash runway | LGVN Quarterly Report (10-Q)stocktitan.net · May 2026Longeveron Announces 2025 Full Year Financial Results and Provides Business Updatefinance.yahoo.com · Mar 2026Longeveron raises $15.9M in private placement | LGVN SEC Filing - Form 8-Kstocktitan.net · Mar 2026Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offeringglobenewswire.com

Frequently asked questions

What does Longeveron do?
Longeveron is a clinical-stage biotechnology company developing regenerative cell therapies for patients with serious and aging-related conditions. Its programs target rare pediatric heart diseases such as Hypoplastic Left Heart Syndrome and Pediatric Dilated Cardiomyopathy, as well as Alzheimer's disease and aging-related frailty.
Who founded Longeveron?
Longeveron was founded by Joshua M. Hare.
Who are Longeveron's investors?
Longeveron's investors include Maryland TEDCO, TEDCO.
How much funding has Longeveron raised?
Longeveron has disclosed $37.4M raised across 4 of its 9 known rounds.
Where is Longeveron headquartered?
Longeveron is headquartered in Miami, US.
Longeveron — Investors & Founders | Fundraising Fox